RxDoctor Payments Data

Luis Chug, MD

Pulmonary Disease · Houston, TXNPI 1326207648

Payments from drug & device makers

$9,597in general payments, 2019–2025

Across 436 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$1K
  • Boehringer Ingelheim$883
  • Electromed, Inc.$683
  • Sanofi$571
  • Philips North America LLC$544
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$1,95020%
  • Food & beverage$7,53078%
  • Education$1171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,597 in reported general payments places this provider in the 70th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$158,860
Medicare patients
211
Services billed
2,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter230$171,971
Dupixent PenDupilumab14$53,744
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$37,626
Breo ElliptaFluticasone/Vilanterol54$29,558
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$3,798
Albuterol Sulfate HfaAlbuterol Sulfate98$2,001
Ventolin HfaAlbuterol Sulfate18$1,094
BreynaBudesonide/Formoterol Fumarate17$1,037
Potassium Chloride56$943
Montelukast Sodium82$803
Wixela InhubFluticasone Propion/Salmeterol12$749
Furosemide82$334
Fluticasone Propionate31$253
Azithromycin38$146
Prednisone59$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$3,064$201,529284 claims
AstraZenecaBreztri Aerosphere$1,106$37,62650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →